http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2008201395-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20ce639c4c23d43ae748d164c78783a0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-602 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2002-91558 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-915 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-148 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate | 2008-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3107124f61dac6d869b1662d680a7faa |
| publicationDate | 2013-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2008201395-B2 |
| titleOfInvention | Short term sustained drug-delivery system for implantable medical devices and method of making the same |
| abstract | A short-term sustained drug eluting coating for implantable medical devices is disclosed. The coating comprises a biocompatible matrix and at least one pharmacologically or biologically active agent and releases substantially one of all of 5 its payloads within four to six weeks post-implantation. When a combination of pharmacological agents are incorporated in the disclosed sustained drug eluting matrix of a drug/device combination, at least one agent is preferred to substantially release in a short duration. Medical devices benefiting from such a desired sustained drug eluting coating include drug eluting cardiovascular, peripheral, and 10 neurovascular stents, abdominal aortic aneurysm (AAA) prosthesis, anastomosis shunt, arterial/venous (AV) shunts etc. One embodiment of the invention is a sustained release coating or depot on or in a stent that releases substantially all of it payload for ischemic myocardial injury after a heart attack. The coating may be formed from biocompatible stable and absorbable polymers of natural and synthetic 15 origins. Useful pharmacological agents for inhibiting vascular neointimal growth post-angioplasty that leads to restenosis include macrolide polyenes such as a rapamycin and all its derivatives and analogs; paclitaxel and all derivatives and analogs. Useful agents for other vascular conditions such as vulnerable plaques may comprise anti-inflammatory, anti-proliferative agents, and matrix metalloprotease 20 (MMP) inhibitors. 26/03/08,kn 17213 spcification,30 14 0- 18C 23c 20 2 .- 30 o o O 230b |
| priorityDate | 2007-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 458.